Latest news about Bacil Pharma
Bacil Pharma
50.17
-0.05(-0.10%)
Company Performance:
View Company Insights1D-0.10%
1M-11.91%
6M+22.55%
1Y+27.08%
5Y+582.59%
More news about Bacil Pharma
23Feb 26
Norbexi Industries Limited Completely Divests 14.46% Stake in Bacil Pharma Limited
Norbexi Industries Limited has completely divested its 14.46% stake in Bacil Pharma Limited, selling 2,075,000 shares through an off-market transaction on February 19, 2026. The disclosure filed under SEBI regulations shows the company's complete exit from its investment in the pharmaceutical firm, reducing its holding from 14.46% to zero. The transaction was executed off-market and represents a significant change in Norbexi Industries' investment portfolio.
13Feb 26
Bacil Pharma Reports Strong Q3FY26 Turnaround with ₹3.92 Lakh Profit
Bacil Pharma Limited reported strong Q3FY26 results with a profit of ₹3.92 lakhs versus a loss of ₹6.20 lakhs in Q3FY25. Nine-month profit surged 85.98% to ₹72.17 lakhs from ₹38.81 lakhs YoY. The company demonstrated effective expense management while maintaining revenue growth, with total expenses declining 61.08% in Q3FY26.
30Dec 25
Khem-Sum Apparels Overseas Ltd. Disposes Complete Stake in Bacil Pharma Limited
Khem-Sum Apparels Overseas Ltd. has completely disposed of its 200-share holding in Bacil Pharma Limited through an off-market sale on December 29, 2025. The promoter group entity's stake has been reduced from 0.001% to zero, representing a complete exit from the pharmaceutical company. The transaction was disclosed under SEBI regulations on December 30, 2025.
29Dec 25
Bacil Pharma Promoter Suman P. Shah Sells Shares
Bacil Pharma Limited received a substantial disposal disclosure from promoter Suman P. Shah. The promoter sold 500 equity shares through market transactions on December 24, 2025, reducing their shareholding from 0.00% to zero. The company's total equity base of 14,353,000 shares remains unchanged.
19Dec 25
Bacil Pharma Limited Appoints New Company Secretary Following Recent Resignation
Bacil Pharma Limited announced the proposed appointment of Mr. Dikshant Singh Panwar as Company Secretary, replacing Bhavana Phoolchand Tak who resigned effective December 1, 2025. The new appointee holds membership number ACS42741 and has extensive compliance experience. The appointment requires board confirmation and follows SEBI regulatory requirements.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
